| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/14756366.2011.641015 |
| P698 | PubMed publication ID | 22145736 |
| P50 | author | Claudiu T Supuran | Q28211545 |
| P2093 | author name string | Alfonso Maresca | |
| Fabrizio Carta | |||
| Daniela Vullo | |||
| P2860 | cites work | Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans | Q27653101 |
| Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct--an inhibitor mimicking the sulfonamide and urea binding to the enzyme | Q27658617 | ||
| Carbonic anhydrase inhibitors | Q28219057 | ||
| Carbonic anhydrases: novel therapeutic applications for inhibitors and activators | Q28263238 | ||
| Structure and function of carbonic anhydrases from Mycobacterium tuberculosis | Q28486815 | ||
| Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis | Q28486849 | ||
| Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate | Q28487300 | ||
| Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273 | Q28487474 | ||
| Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis | Q28909148 | ||
| Potent inhibitory effects of benzyl and p-xylidine-bis dithiocarbamate sodium salts on activities of mushroom tyrosinase | Q33491745 | ||
| Brucella carbonic anhydrases: new targets for designing anti-infective agents | Q33684921 | ||
| Characterization and inhibition studies of an α-carbonic anhydrase from the endangered sturgeon species Acipenser gueldenstaedti. | Q33838825 | ||
| Carbonic anhydrases: current state of the art, therapeutic applications and future prospects | Q34361209 | ||
| The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets | Q37108508 | ||
| A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment | Q37257884 | ||
| Emerging drugs for active tuberculosis | Q37276893 | ||
| Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis | Q37349855 | ||
| Recent advances in antituberculous drug development and novel drug targets | Q37754884 | ||
| Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms | Q37783942 | ||
| The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. | Q37785567 | ||
| Carbonic anhydrase inhibitors and activators for novel therapeutic applications | Q37909406 | ||
| Interfering with pH regulation in tumours as a therapeutic strategy | Q37933052 | ||
| Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? | Q41949186 | ||
| Carbonic anhydrase inhibitors | Q43042271 | ||
| Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate | Q43170759 | ||
| Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. | Q43257307 | ||
| Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium | Q45163943 | ||
| Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions | Q46095908 | ||
| Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides | Q58863214 | ||
| P433 | issue | 2 | |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| P304 | page(s) | 407-411 | |
| P577 | publication date | 2011-12-06 | |
| P1433 | published in | Journal of Enzyme Inhibition and Medicinal Chemistry | Q15708877 |
| P1476 | title | Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosis | |
| P478 | volume | 28 |
| Q46774097 | 7-Amino-3,4-dihydro-1H-quinolin-2-one, a compound similar to the substituted coumarins, inhibits α-carbonic anhydrases without hydrolysis of the lactam ring. |
| Q48334768 | A Key Opinion Leader interview: insight into the research and career of Prof. Claudiu T Supuran |
| Q31140231 | A class of carbonic anhydrase I - selective activators. |
| Q38543994 | Acetazolamide for the treatment of idiopathic intracranial hypertension |
| Q48021639 | Anion inhibition studies of a beta carbonic anhydrase from the malaria mosquito Anopheles gambiae. |
| Q38102786 | Antiglaucoma carbonic anhydrase inhibitors: a patent review |
| Q36171517 | Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates |
| Q38559435 | Bacterial, fungal and protozoan carbonic anhydrases as drug targets. |
| Q58585935 | Carbonic Anhydrase Inhibitors as Novel Drugs against Mycobacterial β-Carbonic Anhydrases: An Update on and Studies |
| Q46279624 | Cloning, expression and biochemical characterization of a β-carbonic anhydrase from the soil bacterium Enterobacter sp. B13. |
| Q33798397 | Copper complexation screen reveals compounds with potent antibiotic properties against methicillin-resistant Staphylococcus aureus |
| Q27702913 | Crystal structure and kinetic studies of a tetrameric type II β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae |
| Q57300400 | Crystallography and Its Impact on Carbonic Anhydrase Research |
| Q48710407 | Dipotassium-trioxohydroxytetrafluorotriborate, K₂[B₃O₃F₄OH], is a potent inhibitor of human carbonic anhydrases |
| Q41491551 | Dithiocarbamates with potent inhibitory activity against the Saccharomyces cerevisiae β-carbonic anhydrase. |
| Q38733892 | Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors |
| Q38102745 | Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors |
| Q38653464 | How many carbonic anhydrase inhibition mechanisms exist? |
| Q35168873 | Identification of metal dithiocarbamates as a novel class of antileishmanial agents |
| Q38742510 | Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity |
| Q40110123 | Inhibition of the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa with monothiocarbamates. |
| Q46544659 | Inhibition studies of quinazoline-sulfonamide derivatives against the γ-CA (PgiCA) from the pathogenic bacterium, Porphyromonas gingivalis |
| Q40381739 | Interplay between a cytosolic and a cell surface carbonic anhydrase in pH homeostasis and acid tolerance of Leishmania. |
| Q39782661 | Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases |
| Q38266496 | Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade. |
| Q48110370 | Primary mono- and bis-sulfonamides obtained via regiospecific sulfochlorination of N-arylpyrazoles: inhibition profile against a panel of human carbonic anhydrases. |
| Q38221060 | Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors. |
| Q47756079 | Sulfocoumarin-, Coumarin-, 4-Sulfamoylphenyl-Bearing Indazole-3-carboxamide Hybrids: Synthesis and Selective Inhibition of Tumor-Associated Carbonic Anhydrase Isozymes IX and XII. |
| Q92582060 | Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase |
| Q53298711 | Synthesis of 3,4-dihydroxypyrrolidine-2,5-dione and 3,5-dihydroxybenzoic acid derivatives and evaluation of the carbonic anhydrase I and II inhibition. |
| Q38263008 | Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium |
| Q27700041 | X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors |
| Q40166814 | β-CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. |
Search more.